Background: In nations with weaker economies, women of reproductive age and young children of growing age are particularly vulnerable to iron deficiency anemia (IDA), a very painful illness. Traditional oral iron salts have adverse effects on the gastrointestinal tract and low absorption. Increased absorption is linked to liposomal iron without having any notable negative consequences. Objective: This study aimed to assess liposomal iron versus iron fumarate in pregnant women with mild anemia. Patients and methods: A randomized control study included 100 pregnant females with mild anemia (Hb 9 - 11 mg/dl) randomized to either the liposomal iron group or iron fumarate group. Results: In this study, Hb at 28-32 weeks was significantly higher in the liposomal iron group (11.18 ± 0.44) than in the ferrous iron group (10.70 ± 0.39). There wasn't significant difference among the studied groups regarding Hb before treatment and Hb at 20 weeks. (p > 0.05). Conclusion: Liposomal carriage of iron is linked to targeted delivery of iron and enables lower doses to be administered due to direct absorption into the bloodstream without the need for protein carriers. It is also associated with reduced exposure to gastric contents, decreased interaction with food contents, and no exposure to various digestive juices. Clinical research suggests that liposomal iron dramatically raises hemoglobin and ferritin levels in both pregnant women and women with iron insufficiency. Compared to standard dosages of ferrous sulphate, using smaller quantities of liposomal iron proved to be successful.